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Abstract 
It is the position of the Academy of Nutrition and Dietetics (the Acad-
emy) that dietary fat for the healthy adult population should provide 
20% to 35% of energy, with an increased consumption of n-3 polyun-
saturated fatty acids and limited intake of saturated and trans fats. The 
Academy recommends a food-based approach through a diet that in-
cludes regular consumption of fatty fish, nuts and seeds, lean meats and 
poultry, low-fat dairy products, vegetables, fruits, whole grains, and le-
gumes. These recommendations are made within the context of rap-
idly evolving science delineating the influence of dietary fat and specific 
fatty acids on human health. In addition to fat as a valuable and calori-
cally dense macronutrient with a central role in supplying essential nu-
trition and supporting healthy body weight, evidence on individual fatty 
acids and fatty acid groups is emerging as a key factor in nutrition and 
health. Small variations in the structure of fatty acids within broader cat-
egories of fatty acids, such as polyunsaturated and saturated, appear to 
elicit different physiological functions. The Academy recognizes that sci-
entific knowledge about the effects of dietary fats on human health is 
young and takes a prudent approach in recommending an increase in 
fatty acids that benefit health and a reduction in fatty acids shown to in-
crease risk of disease. Registered dietitian nutritionists are uniquely po-
sitioned to translate fat and fatty acid research into practical and effec-
tive dietary recommendations.   
digitalcommons.unl.edu
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Position Statement 
It is the position of the Academy of Nutrition and Dietetics that dietary fat for the 
healthy adult population should provide 20% to 35% of energy, with an increased 
consumption of n-3 polyunsaturated fatty acids and limited intake of saturated and 
trans fats. The Academy recommends a food-based approach through a diet that 
includes regular consumption of fatty fish, nuts and seeds, lean meats and poultry, 
low-fat dairy products, vegetables, fruits, whole grains, and legumes.  
This Academy of Nutrition and Dietetics position paper includes the authors’ in-
dependent review of the literature in addition to a systematic review conducted us-
ing the Academy’s Evidence Analysis Process and information from the Academy’s 
Evidence Analysis Library. Topics from the Evidence Analysis Library are clearly de-
lineated. The use of an evidence-based approach provides important added bene-
fits to earlier review methods. The major advantage of the approach is the more rig-
orous standardization of review criteria, which minimizes the likelihood of reviewer 
bias and increases the ease with which disparate articles can be compared. For a 
detailed description of the methods used in the Evidence Analysis Process, go to 
www.andevidencelibrary.com/eaprocess. 
Conclusion Statements are assigned a grade by an expert work group based 
on the systematic analysis and evaluation of the supporting research evidence: 
▪ Grade I = Good 
▪ Grade II = Fair 
▪ Grade III = Limited 
▪ Grade IV = Expert Opinion Only 
▪ Grade V = Not Assignable (because there is no evidence to support or refute the 
conclusion). 
See grade definitions at: www.andevidencelibrary.com. 
Evidence-based information for this and other topics can be found at www.an-
devidencelibrary.com. Subscriptions for nonmembers are purchasable at: www.an-
devidencelibrary.com/store.cfm.  
�  �  �
This is an update of the 2007 Dietary Fatty Acid Position Paper developed by 
the Academy of Nutrition and Dietetics (the Academy; formerly the Amer-
ican Dietetic Association) and the Dietitians of Canada.1 This update and 
the associated position reflect the current opinions of the Academy and is 
based on the most current scientific literature with consideration of other 
academic or organizational body recommendations.2-6 The objectives of the 
current position paper are to provide information on specific fatty acids in-
cluding structure, current and recommended intakes, function, and impact 
on health. This position paper evaluates the evidence for both beneficial and 
adverse effects of dietary fatty acids for the purpose of providing a rationale 
for intake levels of total fat, n-3 and n-6 polyunsaturated fatty acids (PUFA), 
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monounsaturated fatty acids (MUFA), saturated fatty acids (SFA), and trans-
fatty acids (TFA) for healthy individuals. From this, a position has been devel-
oped that will guide registered dietitian nutritionists (RDNs) in their practice 
and dietetic technicians, registered (DTRs) who work under the supervision 
of the RDN in counseling healthy individuals. As the stated position reflects 
recommendations for fatty acid intakes in the context of healthy individu-
als, it will not provide dietary guidance for children, pregnant women, or 
specific disease states. 
Fatty acids are the major form of dietary fat and primarily exist in foods 
in the triglyceride form. Although fatty acids are often categorized by their 
saturation status (e.g., monounsaturated, saturated), understanding the role 
of individual fatty acids on health, rather than as a group, is important. Be-
cause of this, fatty acids will be presented individually in the following order: 
polyunsaturated, monounsaturated, saturated, and trans. In addition, fatty 
acids are consumed as a part of foods that contain other nutrients and di-
etary compounds; these have both additive and synergistic effects on health 
and interact in complex ways that are difficult to delineate. Therefore, the 
roles of individual fatty acids within the broader context of food and dietary 
patterns will be discussed. 
Fatty Acid Classification System 
Fatty acid structures vary considerably by both hydrocarbon chain length 
and saturation status. Although carbon chain length can vary from 2 to 40 
carbons, most dietary fatty acids contain 12 to 22 carbons.7 Fatty acids are 
often categorized into short chain (up to 6 carbons), medium chain (8 to 12 
carbons), or long chain (>12 carbons). Although hydrocarbon chain length is 
an important determinant of function, fatty acids are often classified based 
on whether or not the fatty acid carbon chain contains no double bonds 
(SFA), one double bond (MUFA), or more than one double bond (PUFA), 
as well as the configuration of the double bonds (cis or trans). In addition, 
PUFAs are often further classified based on the position of the first double 
bond from the fatty acid methyl terminus, creating n-3 and n-6 fatty acids. 
In n-3s, the first double bond occurs at the third carbon of the fatty acid 
chain from the methyl (or omega) end, and in n-6s, the first double bond 
occurs at the sixth carbon in the fatty acid chain.8 Figure 1 presents nomen-
clature and common food sources of dietary fatty acids. It is the differences 
in chain length and saturation status that dictate their performance in food 
and cooking, as well as their role in the body and impact on human health 
and disease risk. 
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Name  Common  Nomenclature  Common food sourcesb  
  abbreviationa 
Polyunsaturated fatty acids  PUFA 
n-3 
 α+-linolenic acid  ALA  C18:3  Flax, chia, walnuts, canola oil 
 Stearidonic acid  SDA  C18:4  GMOc soybean oil 
 Eicosapentaenoic acid  EPA  C20:5  Fish and seafood 
 Docosapentaenoic acid  DPA  C22:5  Fish and seafood 
 Docosahexaenoic acid  DHA  C22:6  Fish and seafood 
n-6 
 Linoleic acid  LA  C18:2  Soybean oil, corn oil, shortening 
 γ-linolenic acid  GLA  C18:3  Not commonly found in food 
 Arachidonic acid  ARA  C20:4  Meat, poultry, eggs 
 Conjugated linoleic acid  CLA  C18:2 (variants)  Ruminant meat and dairy 
Monounsaturated fatty acidsd  MUFA 
 Palmitoleic acid   C16:1  Macadamia nuts, blue-green   
        algae 
 Oleic acid   C18:1  Olive oil, canola oil, beef tallow,   
         lard, avocado 
Saturated fatty acids  SFA 
 Carprylic acid  MCTe  C8:0  Coconut oil, palm kernel oil 
 Capric acid  MCT  C10:0  Coconut oil, palm kernel oil 
 Lauric acid  MCT  C12:0  Palm kernel oil, coconut oil 
 Myristic acid   C14:0  Beef tallow, cocoa butter 
 Palmitic acid   C16:0  Palm oil, most fats and oils 
 Stearic acid   C18:0  Meat (lard, beef tallow), fully  
       hydrogenated vegetable oils 
Trans-fatty acids  TFA 
 Elaidic acid   C18:1, t9  Partially hydrogenated    
        vegetable oils 
 Vaccenic acid   C18:1, t11  Butterfat, meat 
a. Only fatty acids with common abbreviations are listed. 
b. Food sources of naturally occurring fatty acids are listed (with exception of GMO soybean oil); for-
tified food and supplement sources can be found in body of paper. 
c. GMO=genetically modified organism. 
d. Only monounsaturated fatty acids (MUFA) in the cis configuration are listed. MUFAs with trans con-
figuration are listed under trans fatty acids. 
e. MCT=medium-chain triglyceride. 
Figure 1. Nomenclature and common food sources of dietary fatty acids.  
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Total Fat vs Individual Fatty Acids 
Total fat intake has been the primary focus of dietary recommendations, with 
increased emphasis on the health impact of individual fatty acids in recent 
years. Total fat intake of 20% to 35% of energy is recommended by the In-
stitute of Medicine and the Food and Agriculture Organization of the United 
Nations (FAO) and is supported by the 2010 Dietary Guidelines for Ameri-
cans (DGA).5,9 The American Heart Association (AHA) and National Choles-
terol Education Program recommend 25% to 35% of daily calories from fat.3,4 
These total fat intake recommendations are based on evidence that indicates 
consumption outside of these ranges is associated with a greater intake of 
energy and SFA (fat intake >35%) or greater intake in carbohydrate (fat in-
take <20%); higher intake of carbohydrate leads to increases in plasma tri-
glyceride and reductions in high-density lipoprotein (HDL) cholesterol lev-
els. According to the National Health and Nutrition Examination Survey 
(NHANES) 2009-2010, 33% of calories in the diets of both women and men 
came from fat, which is near the recommended upper limit of 35%.10 It is 
important to note that individuals often eat more than their energy needs, 
and examining total fat intake as a percentage of calories might well reflect 
more fat in the diet than is recommended and necessary. 
Although total fat recommendations have been emphasized, for ex-
ample, low-fat diet (<20%); moderate-fat diet (20% to 35%); or high-fat 
diet (>35%), the importance of individual fatty acids has been overlooked. 
Achieving intake of total fat within the recommended range (20% to 35%) 
is an important goal, but the quality of fat in the diet is equally important. 
Altering fat consumption, for example, the unsaturated/saturated fat bal-
ance, instead of reducing total fat might be more advantageous to health 
and chronic disease risk reduction.11 In tissues, an increase in concentration 
of one fatty acid corresponds to the reduction of the same magnitude of 
another fatty acid.12 The displacement or replacement of the quality of fatty 
acid is important to consider. 
Recent recognition that individual fatty acids have differing effects on 
health, even within the conventional fat categories, has brought examina-
tion of these fatty acids into the forefront. Although this reductionist view-
point allows for understanding specific fatty acid functions and is important 
in determining which fatty acids are best for health, examination of the foods 
containing these fatty acids is also important. Knowledge of the individual 
fatty acids in foods provides a foundation for the RDN to make whole food 
recommendations to their clients. The variety of fatty acids in common fats 
and oils is provided in Table 1. Additional information on individual fatty 
acids in foods can be found at the US Department of Agriculture’s Nutrient 
Database (http://ndb.nal.usda.gov).13 
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Differing, Wide-Ranging Impacts on Health 
The structure of each fatty acid differs, so it is reasonable that individual fatty 
acids might have unique impacts on health. The impact of specific fatty ac-
ids on disease incidence is difficult to elucidate, as chronic disease devel-
ops over many years and is the culmination of many genetic and lifestyle 
factors. This complexity makes randomized controlled trials of dietary in-
terventions largely impractical, but these trials, coupled with observational, 
epidemiologic, and mechanistic studies, provide valuable evidence on the 
health effects of dietary fat and specific fatty acids. Because healthy individ-
uals are the focus of this paper, the impact of fatty acid intake on those with 
chronic diseases is not discussed. However, despite not having established 
Table 1. Fatty acid profiles of select animal and vegetable fats and oilsa 
               EPAe 
               DPAf  
Lipid  Quantity  SFAb  8:0  10:0  12:0  14:0  16:0  18:0  MUFAc  18:1  PUFAd  18:2  18:3  DHAg  ARAh  TFAi 
Avocado oil  1 Tbsp  11.9  0.0  0.0  0.0  0.0  11.3  0.7  72.6  69.9  13.9  12.9  1.0  0.0  0.0  0.0 
Beef tallow  1 Tbsp  46.8  0.0  0.0  0.9  3.5  23.5  17.8  39.3  33.9  3.8  2.9  0.6  0.0  0.0  0.0 
Butter j  1 Tbsp  53.6  5.1  2.6  2.7  7.8  22.6  10.4  22.0  20.8  3.2  2.9  0.4  0.0  0.0  0.0 
Canola oil  1 Tbsp  7.6  0.0  0.0  0.0  0.0  4.4  6.8  65.1  63.5  29.0  19.6  9.4  0.0  0.0  0.4 
Coconut oil*  1 Tbsp  86.8  7.4  5.9  44.9  16.9  7.9  2.9  5.9  5.9  1.5  1.5  0.0  0.0  0.0  0.0 
Corn oil  1 Tbsp  12.9  0.0  0.0  0.0  0.0  10.6  1.8  27.6  27.4  54.7  53.5  1.2  0.0  0.0  0.3 
Flaxseed oil  1 Tbsp  9.0  0.0  0.0  0.0  0.1  5.1  3.4  18.5  18.3  67.9  14.3  53.4  0.0 0.0  0.1 
Grapeseed oil  1 Tbsp  9.6  0.0  0.0  0.0  0.1  6.7  2.7  16.1  15.8  69.9  69.6  0.1  0.0  0.0  — 
Lard  1 Tbsp  36.9  0.0  0.1  0.2  1.3  22.4  12.7  42.5  38.8  10.5  9.6  1.0  0.0  0.0  0.0 
Olive oil  1 Tbsp  13.7  0.0  0.0  0.0  0.0  11.2  1.9  72.4  70.7  10.4  9.7  0.7  0.0  0.0  — 
Palm oil  1 Tbsp  49.3 0.0  0.0  0.1  1.0  43.5  4.3  37.0  36.6  9.3  9.1  0.2  0.0  0.0  — 
Palm kernel oil  1 Tbsp  81.5  3.3  3.7  47.1  16.4  8.1  2.8  11.4  11.4  1.6  1.6  0.0  0.0  0.0  — 
Rice bran  1 Tbsp  19.7  0.0  0.0  0.0  0.7  16.9  1.6  39.3  39.1  35.0  33.4  1.6  0.0  0.0  — 
Salmon oil  1 Tbsp  19.9  —  —  —  3.3  9.9  4.3  29.0  17.0  40.3  1.5  1.0  31.3  0.7  — 
Soybean oil  1 Tbsp  15.7  0.0  0.0  0.0  0.0  10.4  4.4  22.8  22.6  57.7  51.0  7.1  0.0  0.0  0.5 
a. Listed as percent of total fatty acid content. Based on 13.6 g fatty acids/tablespoon (Tbsp). Cells without numbers did not have data 
in US Department of Agriculture Nutrient Database. 
b. SFA=saturated fatty acid. 
c. MUFA=monounsaturated fatty acid. 
d. PUFA=polyunsaturated fatty acid. 
e. EPA=eicosapentaenoic acid. 
f. DPA=docosapentaenoic acid. 
g. DHA=docosahexaenoic acid. 
h. ARA=arachadonic acid. 
i. TFA=trans-fatty acid. 
j. Butter contains 16% water and therefore the percentages are unable to be directly compared with percentages of the other fats/oils.  
* Values for Coconut oil corrected following Erratum, JAND 114:4 (April 2014), p. 644. doi 10.1016/j.jand.2014.02.014
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or diagnosed disease, “healthy” individuals can possess disease risk factors 
(e.g., elevated low-density lipoprotein [LDL] cholesterol, glucose, obesity) 
that are influenced by specific fatty acid intake. Modulation of known and 
emerging risk factors, such as chronic low-grade inflammation, through di-
etary fatty acid intake can beneficially impact development of common dis-
eases, such as cardiovascular disease, diabetes, and depression, as well as 
emerging diseases, such as Alzheimer’s and dementia. For example, evidence 
from randomized clinical trials and observational studies provide convinc-
ing argument that inadequate intake of long-chain n-3 fatty acids is asso-
ciated with an increased risk of sudden cardiac death.14 Targeting multiple 
risk factors through modulation of diet, specifically fatty acids, holds prom-
ise for promoting public health and attaining meaningful reductions in dis-
ease risk in healthy individuals. 
Need for Knowledge 
Fatty acids can no longer be viewed in general categories, such as satu-
rated and unsaturated, because individual fatty acids within these cate-
gories have different influences on health status and disease risk. For ex-
ample, both stearic acid (18:0) and palmitic acid (16:0) are saturated fats, 
differing only in chain length by two carbons, but they appear to have dif-
ferent effects on circulating LDL cholesterol.15 Another example is the dif-
ference between the location of the first double bond on the fatty acid 
carbon chain. Whether the double bond is located on carbon number 3 
or 6 (as in n-3 and n-6 PUFA) makes a remarkable difference in biological 
function (e.g., vasoconstriction vs vasodilation). Therefore, understanding 
the breadth of information while delineating specifics about individual di-
etary fatty acids is essential. RDNs have the opportunity and responsibil-
ity to translate research into practice for the population at large. National 
organizations specializing in evidence-based dietary recommendations 
are valuable resources. Table 2 summarizes intake recommendations for 
dietary fatty acids. 
This section of the position paper includes the results of a systematic re-
view of literature conducted using the Academy’s Evidence Analysis Process 
and information from the Academy’s Evidence Analysis Library. In this pro-
cess, expert work groups identified dietetic practice-related topics, priori-
tized and selected questions, performed systematic reviews, and developed 
and rated a conclusion statement for each question. The workgroups used 
the Academy’s process to answer a total of three questions related specifi-
cally to dietary fatty acids. 
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Table 2. Dietary fatty acid intake recommendationsa 
Organization  Total fat (%)  PUFAb (n-3)  PUFAc (n-6)  MUFAd  SFAe  TFAf 
2010 Dietary  20-35  Use oils to replace solid fats Use oils to Replace solid  <10%  As low as 
Guidelines for   where possible Increase the replace solid fats fats with MUFAs,  possible  
Americans   amount and variety of seafood  where possible possibly through 
  consumed by choosing seafood   adopting a  
  in place of some meat and poultry      Mediterranean  
    dietary pattern  
US Dietary  20-35 AIg for ALAh is 1.1-1.6 g/day 5%-10% of  As low as As low as 
Reference Intake     or 0.6%-1.2% of intake; up  intake; AI for LAk  possible   possible  
  to 10% can be EPAi+DHAj   is 12-17 g/day   
Academy of  20-35  0.6%-1.2% of intake as ALA;  3%-10% of intake 15%-20% Goal of <7%, <1% 
Nutrition and   500 mg EPA+DHA/day  of intake maximum  
Dietetics         intake of 10%  
American Heart  25-35 Eat fish (particularly fatty fish) LA as 5%-10% Replace  <7% <1% 
Association    at least 2x/week  of intake  animal fats  
    in the diet   
WHO/FAOl  20-35  0.5%-2% of intake; minimum  AI for LA is   Intake at no 
  0.5% from ALA; 250 mg  2%-3% of  more than 10% 
  EPA+DHA/day  intake   of energy;  
     should be  
     replaced with  
     PUFAs <1% 
EFSAm  20-35  AI for ALA is 0.5% of intake;  AI for LA is 4%  As low as As low as 
  250 mg EPA+DHA/day   of intake    possible   possible 
ISSFALn   ALA 0.7% of intake;  AI for LA 
  minimum 500 mg  2% of intake  
  EPA+DHA/day  
a. Percentages based on total energy intake that meets the needs of the individual. 
b. PUFA=polyunsaturated fatty acids. 
c. Values reported for total n-6 PUFA unless indicated. 
d. MUFA=monounsaturated fatty acids. 
e. SFA=saturated fatty acids. 
f. TFA=trans-fatty acids. 
g. AI=Adequate Intake. AI is a recommended average daily nutrient intake level, based on experimentally derived intake levels or approxima-
tions of observed mean nutrient intake by a group (or groups) of apparently healthy people that are assumed to be adequate. An AI is es-
tablished when there is insufficient scientific evidence to determine an Estimated Average Requirement. 
h. ALA=α-linolenic acid. 
i. EPA=eicosapentaenoic acid. 
j. DHA=docosahexaenoic acid. 
k. LA=linoleic acid. 
l. WHO/FAO=World Health Organization/Food and Agriculture Organization. 
m. EFSA=European Food Safety Authority. 
n. ISSFAL=International Society for the Study of Fatty Acids and Lipids.  
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PUFAs 
Specific Fatty Acids and Food Sources 
PUFAs are triglycerides that contain fatty acids with two or more (poly) dou-
ble bonds. PUFAs are liquid at room temperature and, because they are not 
solid fats, they are often referred to as oils. In recent decades, researchers 
have discovered that the function of PUFAs in human nutrition differ based 
on the fatty acid structure. The most common PUFAs are n-3 and n-6, and 
because humans cannot synthesize them, they are considered essential di-
etary nutrients. 
Dietary fatty acids are oxidized as fuel; incorporated in plasma phos-
pholipids, lipoprotein particles, and cell membranes; or stored as triglycer-
ides. The most abundant PUFAs in the diet are α-linolenic acid (ALA; 18:3n-
3) and linoleic acid (LA; 18:2n-6); both of these fatty acid hydrochains are 
18 carbons in length and are considered the parent fatty acids for n-3 and 
n-6, respectively. 
n-3 and n-6 fatty acids are long-chain fatty acids (18 carbons and lon-
ger) and are distinguished within each group by chain length. In the n-3 
family, ALA and stearidonic acid (SDA; 18:4n-3) are considered the shorter-
chain n-3s, while eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic 
acid (DPA; 22:5n-3), and docosahexaenoic acid (DHA; 22:6n-3) are the lon-
ger-chain n-3s. ALA occurs in plant foods such as nuts, particularly walnuts 
and flax, chia and hemp seeds, and vegetable oils, such as canola and soy-
bean oils. SDA is not typically found in food; very small amounts occur in 
fish and uncommon plant sources (e.g., echium, black currant). In the United 
States, the soybean has been genetically modified to produce oil contain-
ing SDA n-3; the SDA-rich soybean oil has Generally Recognized as Safe ap-
proval in the United States.16 EPA, DPA, and DHA occur in fatty fish and sea-
food, and the best sources are salmon, sardines, tuna, herring, and trout. 
An abundance of foods fortified with EPA and/or DHA from either marine 
or algal sources are now available; called functional foods, examples include 
soy milks and juices, cooking oils, spreads, snack foods and even fish sticks, 
where fortification is in the breading. Availability of functional foods var-
ies by region. Eggs can contain shorter or longer-chain n-3s, as determined 
by the chicken feed. Most of the research on long-chain n-3s has used EPA 
and DHA. DPA is a lesser known n-3; it occurs in fatty fish along with EPA 
and DHA but is particularly rich in seal meat, a traditional food of Eskimos 
and other cultures. Interest in new or unique health contributions from DPA 
is growing. The predominant and best understood n-3 fatty acids are ALA 
from plants and EPA and DHA from fish and seafood. 
In the n-6 family, LA and γ-linolenic acid (GLA; 18:3n-6) are shorter-
chain fatty acids, and arachidonic acid (ARA; 20:4n-6) is a longer chain. 
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Longer-chain n-3 and n-6 fatty acids (≥20 carbons) are sometimes called 
highly unsaturated fatty acids. LA occurs in plant foods; the richest sources 
are soybean, corn, and safflower oils. GLA is not found to any great extent 
in foods and is available through dietary supplements from borage and 
evening primrose oil. The best sources of ARA are meat, poultry, and eggs. 
Conjugated linoleic acid (CLA) is an 18-carbon n-6 PUFA that occurs in 
small amounts in the milk (about 0.3% to 0.6% total dairy fat) and meat of 
ruminants. A conjugated fatty acid is one in which the double bonds occur 
on adjacent carbons. The two major CLA forms are cis-9, trans-11 18:2 (c9, 
t11 18:2) and the trans-10, cis-12 18:2 (t10,c12 18:2). There is usually more 
c9, t11 18:2 in food, while supplements typically contain an equal mixture 
of both forms. For the purpose of food labeling, CLA is classified as an n-6 
fatty acid and not a TFA. One pilot study reported intake of CLA from foods 
at 94.9 mg/day in healthy adults in North America.17 
Within the n-3 and n-6 families, the shorter-chain and longer-chain fatty 
acids make different contributions to human nutrition. ALA n-3 is predomi-
nantly used as a fuel source for β-oxidation and only a small portion is con-
verted to longer-chain fatty acids.18 Desaturase and elongase enzymes are 
required for the conversion of shorter-chain to longer-chain fatty acids. It 
was originally believed that the shorter-chain fatty acids readily converted 
to the longer chains, but contemporary research indicates that n-3 conver-
sion from short chain to long chain in humans is very limited; ALA converts 
to EPA at a rate of 5% to 15%, and <1% of ALA reliably converts to DHA.19,20 
Rate of conversion of these essential fatty acids is determined by the pres-
ence of and competition for the desaturase and elongase enzymes and is 
further influenced by other factors, including sex, diet, health status, and 
genetics.21-24 This explains the interest in genetically engineered SDA; more 
SDA than ALA is converted to EPA because with SDA, the rate-limiting con-
version step requiring delta-6 desaturase is bypassed. Conversion, however, 
is limited; two published human trials reported that about 17% of SDA con-
verts to EPA and there is no conversion from SDA to DHA.25,26 As a result, 
SDA is best considered an EPA-only precursor.27 
Individuals who follow a vegetarian or vegan diet and include no ma-
rine foods in their diet will consume ALA because of its wide distribution in 
plant-sourced foods. Through conversion, ALA will provide some EPA but 
little, if any, DHA.19 Emerging science suggests there is individual variation 
in conversion rate of fatty acids, influenced by genetics and dietary habits, 
including the presence of other fatty acids in the diet. Those who follow a 
vegetarian diet might be more efficient at n-3 conversion, but this has not 
been confirmed.22,28 
As 20-carbon PUFAs, EPA n-3 and ARA n-6 function as eicosanoids. 
Eicosanoids are bioactive mediators and precursors for prostaglandins, 
thromboxanes, and leukotrienes. Eicosanoids are considered hormone-like 
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substances because they are produced when stimulated, rapidly utilized and 
metabolized, and not stored in cells. Prostaglandins, thromboxanes, and leu-
kotrienes are involved with a myriad of physiological and homeostatic activ-
ities, including inflammation modulation, platelet aggregation, cell growth 
and proliferation, smooth muscle contraction, and vasoconstriction and va-
sodilatation. EPA, ARA, and DHA are also involved with gene expression, 
cytokine activity, cell signaling, and immune modulation. The eicosanoids 
produced from EPA and ARA differ from each other in structure, and they 
function in complementary metabolic pathways. Eicosanoids produced from 
ARA have high biological activity and are considered more potent than EPA-
derived eicosanoids. For example, prostaglandins produced from ARA pro-
mote inflammation, serve as vasoconstrictors, and stimulate platelet aggre-
gation, and prostaglandins produced from EPA function as vasodilators and 
anti-aggregators. Eicosanoids derived from ARA are mostly proinflammatory 
but have some anti-inflammatory effects. A balance of eicosanoid synthesis 
in tissues is optimal. Resolvins and neuroprotectins, derived from EPA and 
DHA, respectively, are a new class of modulators that appear to have anti-in-
flammatory and neuroprotective activity.8,29 Finally, DHA is a structural com-
ponent of red blood cell membranes and exists in higher concentrations in 
retina tissue, neuronal cells, liver, and testes.30 
PUFAs from Supplements 
n-3 supplements are widespread in the marketplace. The most common sup-
plement forms of ALA are flax and chia seed oils. SDA supplements from al-
gae are being synthesized. EPA and DHA supplements are made from fish 
oil (typically anchovy, menhaden, and salmon oils), cod liver oil, krill oil, and 
squid (calamari) oil. Generally Regarded as Safe status of up to 3 g/day of 
EPA and DHA from fish oil in healthy people was obtained in 1997.31 Vegetar-
ian sources of EPA and DHA are available from algal sources, and genetically 
engineered supplements are under development. GLA n-6 supplements are 
most often sourced from borage and evening primrose oils. CLA, the con-
jugated n-6 supplement, is synthesized from vegetable oils. 
Current Intake of PUFAs 
NHANES 2009-2010 provided information on dietary intake of n-3s and n-6s 
among adults.10 NHANES reported mean daily intake of ALA among males 
was 1.77 g and 1.38 g among females. Mean daily intake of EPA among men 
was 40 mg and 30 mg for women. Mean daily intake of DHA was 80 mg for 
men and 60 mg for women. There is little difference between mean intakes 
by sex, race/ethnicity, and income. These values have remained quite stable 
as reported in the last NHANES data set (NHANES III 1988-94). For n-6s, the 
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mean daily intake of LA among men was 17.84 g and among women, 13.33 
g. This represents an increase as previous NHANES III data reported a mean 
daily consumption of LA at 14.1 g. Daily consumption of ARA was reported 
as 180 mg for men and 120 mg for women. 
Economic disappearance data for each year from 1909 to 1999 was used 
to estimate consumption of food commodities per capita.32 With regard to 
n-3, availability of ALA increased from 0.39% to 0.72% of energy. In 1909, 
the greatest dietary sources of ALA were fats, dairy, pork, beef, and grains; 
by 1999, sources were soybean oil, dairy, fats, other oils, beef, shortening, 
and nuts. Availability of EPA and DHA has remained virtually unchanged. 
Results for n-6, however, were strikingly different. The availability of LA in-
creased 158%, from 2.79% of energy in 1909 to 7.21% of energy in 1999 
(based on current fatty acid analysis). In 1909, the primary food sources of 
LA were fats, pork, grains, shortening, oils, and nuts. Ninety years later they 
were soybean oil, fats, shortening, other oils, poultry, and nuts. The avail-
ability of ARA has remained unchanged. 
Dietary Recommendations for PUFAs 
The 2005 Daily Reference Intakes recommend 5% to 10% energy from n-6 
and 0.6% to 1.2% of energy from n-3, but it did not set a Recommended 
Dietary Allowance (RDA) or Estimated Average Requirement for either. The 
report did provide an Adequate Intake (AI) for n-6 and n-3. The AI for n-6 
is 17 g/day and 12 g/day for men and women 19 to 50 years, respectively; 
the AI for ALA is 1.6 g/day and 1.1 g/day for men and women age 19 to 
older than 70 years, respectively.9 These intakes are equivalent to 5% to 6% 
energy from LA and 0.5% energy from ALA. Recognizing that differences in 
metabolic function among n-3s existed, the Daily Reference Intake report 
noted that EPA and DHA could provide up to 10% of ALA intake. It is im-
portant to recall that AI recommendations are observed median intakes for 
the US population, not an RDA or an intake of fatty acids shown to confer 
lower risk of disease. 
The DGA recommend that adults consume 8 oz or more of seafood per 
week, or about 20% of the recommended intake of protein foods from a 
variety of seafood (fish and shellfish). For primary prevention of coronary 
heart disease (CHD), the AHA,33 the National Heart Foundation of Austra-
lia,34 and the United Kingdom Scientific Advisory Committee,35 all recom-
mend at least two servings of fish per week, preferably fatty fish, providing 
an average daily intake of 450 to 500 mg EPA and DHA. The same recom-
mendation of two or more servings per week is suggested by the American 
Psychiatric Association36 for support of mental health. An increased intake 
of nuts and seeds is also recommended. Because these foods have greater 
caloric density, they should replace servings of meat and poultry and/or be 
consumed in small portions.5 
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The World Health Organization/Food and Agricultural Organization es-
tablished an upper Acceptable Macronutrient Distribution Range (AMDR) 
for total PUFAs at 11% energy. They recommend total n-3 intake of 0.5% 
to 2% energy, with a minimum requirement of >0.5% energy from ALA to 
prevent deficiency, and 250 mg EPA and DHA/day for men and nonpreg-
nant women.6 For LA n-6, they recommend an estimated average require-
ment of 2% energy, an AI of 2% to 3% energy, and an AMDR of 2.5% to 9%. 
The lower levels in the range are to prevent deficiency, and the upper level 
is suggested as part of healthy diet for long-term cardiovascular health. The 
European Food Safety Authority recommends an AI of 0.5% energy for ALA 
and an AI of 250 mg EPA and DHA for primary prevention in healthy adults. 
For n-6, the European Food Safety Authority recommends an AI of 4% en-
ergy for LA; they do not give a Dietary Reference Value for ARA.37 The In-
ternational Society for the Study of Fatty Acids and Lipids recommends a 
healthy intake of ALA n-3 as 0.7% energy and for cardiovascular health, a 
minimum of 500 mg/day of EPA and DHA n-3. They also recommended an 
AI of LA n-6 at 2% energy.38 
In 2004, the Food and Drug Administration (FDA)39 approved a Qualified 
Health Claim for n-3 fatty acids and heart disease, stating: “Supportive but 
not conclusive research shows that consumption of EPA and DHA n-3 fatty 
acids may reduce the risk of CHD. One serving of [name of food] provides 
[x] grams of EPA and DHA n-3 fatty acids.” The FDA also approved a Qual-
ified Health Claim for nuts and heart disease as well as walnuts and heart 
disease, stating: “Scientific evidence suggests but does not prove that eat-
ing 1.5 ounces per day of most nuts [such as name of specific nut] as part of 
a diet low in saturated fat and cholesterol may reduce the risk of heart dis-
ease.” The FDA made the same statement for walnuts.40 
Based on recent literature, increasing consumption of PUFAs with a par-
ticular focus on increasing n-3 intake (i.e., striving to consume two or more 
servings of fatty fish per week to provide at least 500 mg EPA and DHA per 
day, and aiming toward an intake of at least 0.5% to 2% energy as n-3 fatty 
acids and 5% to 10% energy as n-6 fatty acids per day) is desirable. 
PUFAs and Health
n-3 Fatty Acids. The role of n-3 fatty acids in heart health is one of the 
most studied areas of nutrition science. Observations specific to long-chain 
n-3 fatty acids were first made in the 1960s when epidemiologists observed 
that Greenland Eskimos and native Alaskans had a low incidence of CHD, al-
though they consumed large amounts of fat. In the 1970s, death rates from 
heart disease among males aged 45 to 64 years were 40% in the United 
States and nearly 35% in Denmark, yet only 5% in Greenland.41 Compared 
to the Danes, Greenland Eskimos had higher blood levels of saturated fat 
and lower levels of PUFAs, cholesterol, and triglycerides, even though both 
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groups ate about the same amount of total fat (Danes 40%; Eskimos 37%). 
The Greenland Eskimos also had considerably higher blood levels (up to 
16%) of the n-3 fatty acid EPA. The researchers noted more of a qualitative 
than quantitative difference with respect to fatty acid composition in the di-
ets.42 Based on these findings, as well as observations in countries that con-
sume large amounts of fish such as Japan, associations between fish con-
sumption and overall cardiovascular mortality and sudden cardiac death 
have been noted. According to a 2011 meta-analysis, observational and 
randomized clinical trial evidence suggests that fish or fish oil consump-
tion can also reduce inflammation, improve endothelial function, normalize 
heart rate variability, improve myocardial relaxation and efficiency, and, at 
higher doses, limit platelet aggregation.43 In addition, inverse relationships 
between blood levels of n-3 and risk for sudden cardiac death have been 
observed.44,45 Habitual fish consumption is associated with lower risk of CHD 
and ischemic stroke and, among the general healthy population, those who 
consume a modest amount of fish or fish oil providing _250 mg EPA and 
DHA/day have a 36% lower risk of fatal heart disease.14 These benefits have 
not been shown among those who eat commercially fried fish or fish sand-
wiches; this might be a reflection of the type of fish commonly fried, as it 
tends to be lower in EPA and DHA content. Nonetheless, researchers have 
shown that consumption of nonfried fish is associated with higher EPA and 
DHA blood levels.46,47 
In addition to providing long-chain n-3s, fish provides lean protein, vi-
tamins, and minerals. Due to the concern of potential methylmercury con-
tamination in fish, in 2004 the US Department of Agriculture48 recommended 
pregnant women and children under 5 years old limit fish consumption and 
avoid the following types of fish: shark, swordfish, king mackerel, and tile-
fish. Since then, an extensive risk-to-benefit analysis concluded that, with 
the exception of select fish, such as those included in the US Department of 
Agriculture advisory, the health benefits of fish consumption outweigh po-
tential risks.49 At this time, however, the US Department of Agriculture advi-
sory remains in effect. Although fish oil supplements have been shown to 
be equally effective as fish at increasing tissue levels of EPA and DHA,50 it is 
unclear whether benefits observed in those with habitual fish consumption 
can be fully reproduced with refined fish oil supplements. Clinical research 
has shown that supplementing with refined fish oil can help reduce triglyc-
erides and improve blood pressure and heart rate levels.51-55 
The benefits of ALA independent of EPA and DHA are not well docu-
mented; but, because it is plant sourced, ALA is more readily available in the 
diet and is a particularly important source of PUFAs for vegetarians. Stud-
ies investigating cardiovascular benefits of ALA in the healthy population 
have shown mixed or inconsistent results.56,57 Diets rich in ALA have been 
reported to lower lipid levels, reduce vascular inflammation, and reduce 
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blood pressure in those with elevated cholesterol levels.58,59 Interestingly, an 
11-country study in Europe reported reductions in CHD in countries that 
consumed ALA-rich canola oil compared to countries that consumed pri-
marily sunflower oil, which contains no ALA.60 Walnuts are a particularly rich 
source of ALA and several studies have reported benefits from ALA by in-
cluding walnuts and a variety of nuts in the diet.61-63 Plant-sources of n-3s 
have also been shown to have a protective effect on bone metabolism.64 
However, a cardioprotective blood level of long-chain n-3s (EPA and DHA) 
cannot be achieved by consuming ALA alone.65,66 
Health benefits of SDA independent of EPA and DHA are unclear. Al-
though little is known about the biological effects of SDA, incorporating 
genetically engineered SDA into the food supply is motivated by barriers to 
fish consumption and global concerns for sustainability. Modulating lipid 
levels with EPA and DHA require relatively high doses; preliminary studies 
indicate that consuming SDA at a bioequivalent dose of EPA (approximately 
4 g SDA = approximately 1 g EPA) has little impact on circulating lipids.26,27 
Depression is an increasingly common mental health disorder. It can be 
chronic or recurrent, and the impact on individuals, families, caregivers, com-
munities, and the work force is significant. It is the leading cause of disabil-
ity worldwide and is predicted to be among the top three leading causes 
of burden of disease by 2030.67 An association between fish consumption 
and incidence of major depression was first reported in 1998.68 Since then, 
a link between low levels of long-chain n-3 fatty acids and depression has 
been observed in a number of trials.69-73 The recommendation by the Amer-
ican Psychiatric Association to consume fatty fish at least twice a week re-
flects these findings.36 
Some level of cognitive decline is considered normal with aging and 
lower levels of DHA have been observed in individuals with cognitive de-
cline and Alzheimer’s disease.74-77 The results of studies examining the rela-
tionship between long-chain n-3s on cognitive decline have been mixed.78-80 
The Academy’s Evidence Analysis Library recently examined this question 
(see Figure 2); 6 of the 14 studies analyzed reported positive associations 
between EPA, DHA, or fish consumption and decreased risk of cognitive 
decline. Results varied based on amount and source of EPA and DHA con-
sumed and, perhaps more importantly, the state of cognitive health at the 
outset of the study. A study evaluating healthy middle-aged adults showed 
that DHA but not ALA or EPA was associated with better performance on 
cognitive tests, such as nonverbal reasoning, mental flexibility, memory, 
and vocabulary.81 
Essential fatty acids are potentially potent anti-inflammatory agents and, 
as such, clinical evidence has shown a role for EPA and DHA in reducing 
symptoms of rheumatoid arthritis.82,83 Currently, there is interest in the role of 
fatty acids in immune health, in part because long-chain fatty acids appear 
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to influence proteins directly involved with immune cell activation.29,84 De-
spite promising results from animal models and cultured tumor cell lines, no 
clear relationship between dietary intake of EPA and DHA and risk for can-
cer have been demonstrated.65 
n-6 Fatty Acids. LA is the most highly consumed PUFA in the Western diet 
and is found in virtually all commonly consumed foods. LA is the meta-
bolic precursor of ARA and there is concern that LA consumption can en-
rich tissues with ARA and contribute to overproduction of bioactive eico-
sanoids, thereby increasing inflammatory markers and/or chronic disease 
Question: What is the effect of eicosapentaenoic acid (EPA)/docosahexaenoic acid 
(DHA) from supplemental and dietary sources on cognitive decline in adults? 
Conclusion: Based on 14 studies (1 case-control, 3 cross-sectional, 6 prospective 
cohort, and 4 randomized controlled trials) primarily of healthy elderly subjects 
or those matched for incident dementia, results are mixed. Six of the 14 studies 
found a positive association of EPA, DHA, or fish consumption and a decreased 
risk of cognitive decline. The majority of the studies included large populations of 
elderly subjects measuring either blood levels of EPA and DHA and fish consump-
tion. Results vary based on dose of supplementation or dietary consumption of 
fish, EPA, or DHA. Further research is needed to determine whether EPA, DHA, and 
fish consumption has a protective effect for all-cause dementia. There is some ev-
idence that ApoE e4 carrier status should be factored into future studies. 
Gradea II=Fair 
Question: What is the effect of linoleic acid (LA) on the risk of diabetes mellitus and/
or insulin resistance in adults? 
Conclusion: There is fair evidence that LA status is inversely associated with risk of 
type 2 diabetes mellitus. Limited studies have shown an inverse relationship be-
tween LA status and risk factors for type 2 diabetes mellitus including insulin re-
sistance, metabolic syndrome, inflammation, nerve function/neuropathy, and the 
liver enzyme, alanine transaminase, as a marker of liver fat. 
Grade II=Fair 
Question: What is the effect of conjugated linoleic acid (CLA) on body composition 
and weight loss in healthy adults? 
Conclusion: Fair evidence indicates that 3 to 6 months of CLA supplementation re-
sults in a decrease in fat mass and an increase in fat-free mass in healthy adults; 
however, fair evidence indicates that CLA does not affect body weight. 
Grade II=Fair 
a. Academy of Nutrition and Dietetics Evidence Analysis Library Grade Definitions 
and Chart: http://andevidencelibrary.com/content.cfm?content_id=11 
Figure 2. Questions, conclusions, and grades from the Dietary Fatty Acids Evidence 
Analysis Project of Academy of Nutrition and Dietetics’ Evidence Analysis Library.
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risk. However, a 2011 review reported that decreasing dietary LA up to 90% 
did not significantly correlate with change in ARA tissue levels and, similarly, 
increasing dietary LA levels did not increase ARA levels substantially. A 2012 
systematic review of randomized controlled trials that assessed the impact of 
LA on biologic markers of chronic inflammation among healthy adults also 
reported no evidence that LA increased inflammatory markers.85 Neverthe-
less, emerging evidence indicates significant racial differences in conversion 
rate of LA to ARA, particularly between those of European and African de-
scent, making this an important area for further learning.86 With regard to 
GLA, a linear relationship between dietary GLA and increases in plasma and 
serum phospholipid ARA levels has been measured.87 
An AHA advisory published in 2009 summarized evidence on n-6 con-
sumption, particularly LA and CHD risk. It reported that consuming 5% to 
10% of energy from n-6 PUFAs reduced the risk of CHD relative to lower in-
takes.88 A more recent meta-analysis, however, challenges this conclusion.89 
Evidence from animal studies suggests a beneficial role for CLA for 
weight loss. However, results from supplementation trials using intake lev-
els of CLA unattainable from food (1.8 to 4.5 g/day) have been mixed.90-92 
The Academy’s Evidence Analysis Library recently reviewed this question 
(see Figure 2). Impaired insulin sensitivity has been reported in some but 
not all studies using CLA supplementation in those with obesity and meta-
bolic syndrome.91-93 
MUFAs 
Specific Fatty Acids and Their Food Sources 
MUFAs are present in a wide variety of foods, including vegetable, nut, and 
seed oils, as well as meats and dairy products. By definition, MUFAs con-
tain one double bond; this double bond varies in location but is frequently 
located at carbon nine from the methyl end of the fatty acid hydrocarbon 
chain. MUFAs also differ based on chain length, and although these fatty ac-
ids can exist from 10 to 32 carbons, the majority exist as an 18-carbon fatty 
acid in the form of oleic acid. 
Oleic acid contains one double bond at carbon nine, with the dou-
ble bond existing in the cis position (18:1 c-9). One of the most abundant 
fatty acids found in foods, oleic acid is present in high amounts in olive and 
canola oils (see Table 1), as well as in avocados and almonds (9.8 g/avocado 
half and 8.8 g/1 oz almonds, respectively). Although these food sources are 
generally well known, at least 30% of the fatty acids in beef tallow, lard, and 
palm oil are oleic acid, and >20% of the fatty acids in both soybean and corn 
oil are oleic acid.13 As a result, oleic acid is the most abundantly consumed 
fatty acid in the American diet at 12% energy intake.10 
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Several other MUFAs exist but are present in foods in low quantities. 
One MUFA that naturally exists in lower quantities in foods is erucic acid, a 
22-carbon fatty acid that contains one double bond at carbon 9 (22:1, c-9). 
Food sources of erucic acid include rapeseed and other plants from the 
Brassicaceae family, including kale and broccoli. Canola oil is produced from 
rapeseed, but removal of erucic acid through genetic modification has es-
sentially eliminated the erucic acid content in canola oil and subsequently 
from the diet. 
In addition to n-9 MUFAs, an n-7 MUFA with a purported health benefit 
is palmitoleic acid, containing 16 carbons with one double bond at carbon 
7 from the methyl end (16:1, c-7). Palmitoleic acid is not commonly found 
in foods, but is a product of palmitic acid (16:0) metabolism in the body. 
Foods that naturally contain palmitoleic acid include certain blue-green al-
gae, macadamia nuts (3.7 g/oz; 17% of fat content), and sea buckthorn oil. 
Although the fatty acids mentioned have one double bond that exists in the 
cis formation, MUFAs can exist in the trans conformation as a result of in-
dustrial hydrogenation; most often these TFA exist as 18:1, t-9. TFAs will be 
discussed in the trans-fat section of this article. Although additional MU-
FAs exist, the quantities consumed through diet are negligible and there-
fore will not be discussed. 
MUFAs from Supplements 
Supplementation with MUFA is not common practice and is not supported 
by authoritative bodies. However, MUFAs are available in supplement form. 
Despite its abundance in various foods and oils, oleic acid from olive oil is 
marketed as a dietary supplement. Given the quantity of oleic acid in com-
mon food oils (9.6 g per Tbsp olive oil; 8.3 g per Tbsp canola oil; 3 g per 
Tbsp soybean oil), supplementing with olive oil does not provide apprecia-
ble quantities compared to the common daily diet. Oleic acid from olive oil 
can also be found in supplements containing the combination of n-3, n-6, 
and n-9 fatty acids; given the abundant supply of both n-6 (18:2) and n-9 
(oleic acid; 18:1) in the diet, the supplemental use of this combination is not 
supported. In addition to oleic acid, palmitoleic acid is currently being mar-
keted as an n-7 fatty acid supplement with claims of preventing or reduc-
ing heart disease. 
Current Dietary Intake of MUFAs 
NHANES 2009-2010 reports the dietary intake of MUFA for both men and 
women was 12% of total energy. This rivals SFA intake (11%) and is nearly 
double that of PUFA intake (7%).10 Of all the fatty acid categories, MUFAs 
are consumed the most, comprising 36% of total fat intake. The majority 
(93%) of MUFA consumption is oleic acid at approximately 27 g/day; second 
to this is palmitoleic acid at 1.2 g/day. MUFA intake has remained relatively 
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stable with an average daily intake of 30.9 g in 2001-2002 vs 28.7 g in 2009-
2010. No differences in MUFA intake currently exist between sex, race, and 
income. Global consumption of MUFA is variable but approximates intake 
in the United States.94 
MUFA Recommendations 
MUFA intake recommendations by authoritative bodies exist as general 
guidelines. There is no AMDR for MUFAs. Although the DGA do not recom-
mend a specific amount of MUFA to consume each day, they do recommend 
replacing solid fats with oils rich in PUFAs and MUFAs, possibly through 
adopting a Mediterranean dietary pattern.5 Similarly, the AHA’s 2006 Diet 
and Lifestyle Recommendations for cardiovascular disease (CVD) risk reduc-
tion in the general population stated PUFAs and MUFAs should replace an-
imal fats in the diet, with a total fat intake of 25% to 35% of energy intake.3 
To date, the most specific recommendation for MUFAs has been the Adult 
Treatment Panel III (2004) recommendation, which states up to 20% of en-
ergy intake as MUFA, thereby comprising a majority of the recommended 
25% to 35% of total fat intake.4 No specific recommendations exist for MUFA 
intake with regard to cancer or diabetes prevention. 
Most US authoritative bodies have not provided percentage intake rec-
ommendations for MUFA; instead, appropriate consumption levels need 
to be extrapolated from the quantity of fat remaining from total fat intake 
recommendations after PUFA and SFA recommendations are met. Indeed, 
a recent FAO report indicated that MUFA intake be calculated by difference 
(Total fat [%E]–SFA [%E]–PUFA [%E]–TFA [%E]).6 This quantity determined 
through calculation by difference allows for up to 15% to 20% of total en-
ergy. While considering intake recommendations for total fat and fatty ac-
ids (discussed in their respective sections), one can extrapolate that MUFAs 
can comprise 9% to 29% of energy in our diet, assuming current intake lev-
els of saturated and trans fat. For example, assuming no change from cur-
rent consumption of saturated and trans fat (approximately 12% combined), 
then MUFA intake should not be more than 17% of energy in order to avoid 
consumption above intake recommendations for total fat. This is important, 
as excess consumption of energy-dense nutrients, such as fatty acids, can 
lead to weight gain and, depending on type of fatty acid, be detrimental to 
health. Based on currently available information, consumption of MUFA at a 
moderate level (15% to 20%) to account for appropriate PUFA intake, while 
keeping within 20% to 35% of energy as fat is desirable. 
MUFAs and Health 
Although current MUFA intake at 12% of energy falls within total fat rec-
ommendations and supports recommended PUFA intake, investigating the 
impact of MUFA in the diet is warranted. This is important because specific 
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intake recommendations for MUFA are limited, specific health benefits of 
MUFAs are unclear, and recent emphasis on olive oil consumption by health 
professionals and the media can result in increases in MUFA intake. Under-
standing the role of MUFAs within the context of substitutions for other mac-
ronutrients is also important. With consumption of oleic acid at 93% of to-
tal MUFA intake, oleic acid is the primary focus in this section. 
Oleic acid can be synthesized in vivo, so measuring serum oleic acid as 
a marker of health does not reflect intake. Although there is an inability to 
assess MUFA status, MUFA intake has been linked to alterations in markers 
of health and disease, such as reducing LDL cholesterol, triglycerides, to-
tal cholesterol to HDL ratio, and increasing HDL cholesterol.95 In the context 
of macronutrient replacement, oleic acid lowers total and LDL cholesterol 
when it replaces SFA (12:0 through 16:0 SFAs).96 Compared to carbohydrate, 
MUFA decreases triglycerides, increases HDL cholesterol, and is inversely re-
lated to total-to-HDL cholesterol ratio. In addition, compared to diets with 
≤12% MUFA, dietary regimens with high amounts of MUFA (>12%) resulted 
in lower fat mass, systolic blood pressure, and diastolic blood pressure.97 
Despite evidence reporting health benefits from MUFA consumption, 
some recent studies have questioned these benefits. From a pooled anal-
ysis of 11 cohort studies, Jakobsen and colleagues reported in 2009 that 
PUFAs are a preferred energy source over both MUFA and carbohydrate; 
the analysis did not show that MUFA provided cardioprotection.98 In addi-
tion, when coronary mortality was assessed over 30 years, serum MUFA lev-
els were positively associated with coronary death.99 In contrast, however, 
there is a large body of evidence reporting health benefits from consuming 
a Mediterranean diet (i.e., a dietary pattern that includes olive oil at approx-
imately 20% of energy intake).100-102 Recent evidence also suggests benefits 
from olive oil consumption for obesity, according to a 14-point screener 
for adherence to the Mediterranean diet (PREDIMED [Prevención con Dieta 
Mediterránea] trial).103 The finding that, compared to a low-fat diet, a Med-
iterranean diet enriched with either olive oil or nuts reduced the incidence 
of major cardiovascular events104 supports potential health benefits from 
olive oil; it should be noted that although the subjects in this study were 
free of heart disease, they were at high cardiovascular risk and might not 
be considered healthy adults, which is the focus of this article. Finally, and 
as recognized in the previously mentioned PREDIMED trial,103 olive oil is 
only one component of the Mediterranean diet. Because the dietary pat-
tern also emphasizes vegetables and fruits, n-3 fatty acid-rich foods, nuts, 
low-fat dairy, and moderate red wine intake, reported benefits of a Medi-
terranean diet on CVD risk factors cannot be attributed solely to the MUFA 
content. Indeed, nut consumption has been shown to reduce total choles-
terol, LDL cholesterol, and postprandial hyperglycemia compared to meals 
high in carbohydrates.61,105 
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In summary, MUFA consumption can be beneficial when replacing car-
bohydrate and saturated fat, but not as beneficial when replacing PUFAs. 
Although MUFA is shown to have positive impact on surrogate markers, the 
potential impact of MUFA intake alone on disease outcomes, such as CVD 
or diabetes, remains unclear. Further understanding of the precise role of 
MUFAs on health and disease when consumed within the context of an eat-
ing pattern (e.g., Mediterranean diet) is warranted. Although most of the re-
search on MUFAs has focused on risk of CVD and associated biomarkers, the 
relationship between MUFAs and cancer has been investigated. The Amer-
ican Cancer Society guidelines state that olive oil is not associated with an 
increased risk of cancer and likely has a neutral effect on cancer risk.106 
SFAs 
Specific Fatty Acids and Food Sources 
SFAs are fatty acids that are fully hydrogenated. SFAs do not contain dou-
ble bonds between carbon atoms in the fatty acid hydrocarbon chain and 
therefore have a linear chain, a structural property that allows the individual 
fatty acids to tightly pack and exist at a solid state at room temperature. SFAs 
vary in length, but most commonly exist in the food supply between 12 and 
18 carbons: lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), and 
stearic acid (18:0). Less common in the food supply are shorter-chain SFAs, 
specifically caprylic (8:0) and capric (10:0). These are medium-chain triglyc-
erides (MCTs), in the category of fatty acids that are 8-12 carbons in length. 
SFAs originate primarily from animal sources, including meats, eggs, and 
butter, or from processed food products containing naturally saturated veg-
etable oils. Animal fats such as butter, lard, and beef tallow predominantly 
contain palmitic acid (16:0) and stearic acid (18:0) (see Table 1). Specifically, 
food fats high in stearic acid (18:0) include beef tallow (19% of fat as 18:0) 
and cocoa butter (33% of fat as 18:0). It should be noted that stearic acid 
does not negatively impact serum cholesterol levels; as a result, foods high 
in stearic acid can affect health in ways different from other SFAs.107 Although 
the primary sources of SFAs are animal products, tropical vegetable oils such 
as palm and palm kernel oil are commonly used in processed foods, princi-
pally because of their physical properties. Although palm oil and palm ker-
nel oil both originate from the oil palm tree, these oils have different fatty 
acid profiles; palm oil contains 49% of fat as SFA (primarily 16:0) and palm 
kernel oil contains 82% of fat as SFA (primarily 12:0). In comparison, 87% of 
the fatty acids in coconut oil (from the coconut palm) are saturated, with 12:0 
in the highest concentration. Although coconut oil is not commonly used 
in processed foods, new food products on the market (e.g., milk, spreads, 
yogurt) containing coconut oil are touting the purported health benefits of 
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MCTs (see section on SFAs and Health). In addition to SFA that occur natu-
rally in foods, vegetable oils are industrially hydrogenated (the process of 
adding hydrogen atoms to unsaturated bonds to create saturated bonds) 
to produce fats that have properties ideal for food production. In this pro-
cess of creating fully hydrogenated fatty acids (SFA), partially hydrogenated 
fatty acids (TFAs) are also produced. 
SFAs from Supplements 
SFAs are not commonly marketed in supplement form; MCTs are an excep-
tion. MCT supplements contain primarily 8:0 and 10:0 fatty acids in capsule 
or liquid form. However, some MCT supplements are derived from coco-
nut oil. More than 50% of the fatty acids in coconut oil are MCTs (58.7% are 
6 to 12 carbons in length) and due to this are marketed as having health-
promoting properties. It is important to note that supplemental MCT oil is 
used for medical nutrition therapy in patients who lack the ability to prop-
erly metabolize longer-chain lipids. Although the MCT oil used for patient 
care often originates from coconut or palm oil and might contain primarily 
12:0 (rather than 8:0 or 10:0) as its fatty acid source, individuals with a med-
ical indication for MCTs differ from the needs of the healthy individual. Cau-
tion should be taken when considering MCT supplements as the impact of 
the different MCT fatty acids on human health are not fully elucidated and 
many over-the-counter supplements do not identify which fatty acids they 
contain (see section on SFAs and Health). 
Current Dietary Intake of SFAs 
On average, both men and women consume 11% of energy from SFAs; this 
is higher than the recommendation from most authoritative bodies to con-
sume <10% of energy as SFA.10 No differences in saturated fat intake exist 
based on race/ethnicity (range of 10.0% to 11.3% of intake) or income. The 
majority of saturated fat consumed is from palmitic acid (16:0) and then 
stearic acid (18:0) (54% and 25% of saturated fat intake, respectively).10 Food 
sources of SFA in the American diet, listed as greatest to least, are cheese, 
pizza, grain-based desserts, and dairy-based desserts; together these foods 
comprise 31% of SFA intake.5 Most stearic acid is consumed from grain-
based desserts, cheese, and various meats.2 From a global perspective, sat-
urated fat intake (based on food availability) varies by continent and coun-
try, with lower intakes in Asia (3.1% to 10.6% of kilocalories) to higher intakes 
in Europe (8.9% to 16.5%). With the diversifying population of the United 
States, identification of global SFA intake and the specific food sources is im-
portant.94 Finally, because energy intake is often greater than energy need, 
evaluating SFA intake solely as a percentage, rather gram quantities, pro-
vides a somewhat limited view. 
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SFA Recommendations 
No current AI or RDA exist, in part because SFA is synthesized in the body 
to meet physiological needs and because of the recognized role of SFA in 
CVD.9 The AMDR states that SFA should be as low as possible while con-
suming a nutritionally adequate diet. The DGA recommend that <10% of 
calories come from saturated fat and should be replaced with MUFA and 
PUFA; <7% SFA intake was suggested for further reduction of CVD risk.5 The 
guidelines also recommend limiting foods that contain solid fats (SFA and 
TFA), sugars, and sodium; this is especially important as these foods com-
prise 19% of total energy intake. 
The AHA’s Diet and Lifestyle Recommendations (2006) recommended 
SFA intake be <7% of calories (approximately 16 g based on a 2,000 kcal 
diet) for the general population for CVD risk reduction.3 In addition, the AHA 
and American College of Cardiology recently released a report indicating a 
dietary pattern that achieves 5% to 6% of calories from saturated fat best for 
those that want to achieve lipid lowering.108 In 2010, the FAO reported that 
SFA intake should be no more than 10% of energy and replaced with PU-
FAs.6 Although the American Diabetes Association has a recent position on 
fat in diabetes management, no recommendations exist for SFA in primary 
prevention of either diabetes or cancer. A current American Cancer Society 
guideline, however, recommends limiting consumption of red and processed 
meats, recognizing their role as major contributors to total and saturated 
fat intake. Based on recent literature and consensus, the goal for SFA intake 
for the population should be 7% to 10% of total energy. The current intake 
of SFA at 11% exceeds the amount recommended for healthy individuals. 
SFAs and Health 
The linear structure of SFA and its ability to tightly pack in cell membranes, 
along with its signaling properties, have consequences often considered 
detrimental to health. As with the other fatty acid groups, individual SFAs 
have differing impacts on health. The SFAs 12:0, 14:0, and 16:0 have similar 
effects on serum lipoproteins; specifically, they increase LDL cholesterol.15 In 
contrast, stearic acid (18:0) has a neutral impact on LDL cholesterol.107 How-
ever, because stearic acid is consumed in foods that should otherwise be 
limited (e.g., grain-based desserts, cheese, processed meat), it is prudent to 
make the same intake recommendations for stearic acid as the other SFAs. 
When evaluating the impact of replacing SFA with carbohydrates on CVD 
risk, SFA increases LDL cholesterol but lowers triglycerides and raises HDL 
cholesterol, and apolipoprotein B is not changed. Inclusion of 12:0, 14:0, 
or 16:0 increases LDL cholesterol and HDL cholesterol when replacing car-
bohydrate at 5% of the diet; however, a recent pooled analysis of large co-
hort studies indicate there is a significantly greater relative risk for CHD with 
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carbohydrate intake vs SFA intake.98 When stearic acid is replaced by carbo-
hydrate, there is a nonsignificant change in these CVD risk factors.95 In ad-
dition, replacing SFA with PUFA lowers CVD risk by approximately 10% (5% 
energy substitution).109 There is limited evidence about any impact of satu-
rated fat on inflammation. Despite documented influence of saturated fat on 
surrogate disease markers, the effect of saturated fat intake on disease end 
points is not clear. A recent systematic review reported insufficient evidence 
to link saturated fat intake with CHD.110 Several studies show that reducing 
fat consumption, especially saturated fat, can reduce risk for diabetes with 
improvements in weight111,112; however, this is not supported by other trials. 
Although known to be an important component of breast milk, MCTs are 
gaining in popularity among healthy adults. Unlike longer chain SFAs, MCTs 
are transported in portal circulation and more readily oxidized through the 
b-oxidation pathway. That these fatty acids are oxidized rather than stored 
as triglyceride in the body could be advantageous. The oxidation rate of 
MCTs, as well as their impact on thermogenesis, has been shown to be ben-
eficial in decreasing adiposity and improving weight loss when compared 
to olive oil.113,114 However, these results were from supplementation with oil 
containing 8:0 and 10:0 and not 12:0 fatty acids. New food products con-
taining coconut oil and other palm oils (e.g., milk, spreads, yogurt) are tout-
ing health benefits of MCTs. Given that 44% of coconut oil is 12:0 and 16% 
is 14:0, and these fatty acids are hypercholesterolemic, consumption of co-
conut products is not currently recommended. 115 There is, however, cause 
to focus on the impact of different MCT fatty acids in human health. As re-
search is completed, the Academy will disseminate findings to RDNs with 
appropriate recommendations. 
Dietary patterns that are high in saturated fat include the Western di-
etary pattern, characterized as high in total fat, saturated and trans fat, re-
fined carbohydrate, and sodium. Although distinguished in part by its satu-
rated fat content, saturated fat is only one component of the Western dietary 
pattern. The saturated fat content of red meat can contribute to disease risk, 
but other components such as iron, sodium, and compounds created when 
cooking red meat can also contribute. Compared to red meat, consump-
tion of fish, poultry, dairy products, and nuts is associated with a lower risk 
of CHD when the same servings are consumed.116 Although this risk reduc-
tion could be due to a reduction in heme iron, sodium, or saturated fat, or 
an increase in PUFA, examining whole foods rather than individual compo-
nents is important. In addition, although evidence on the impact of SFAs 
on disease end points such as heart disease, diabetes, and cancer is mixed, 
replacing of SFA with PUFA instead of refined carbohydrate appears to be 
beneficial. Finally, decreasing SFA without caloric replacement is an effec-
tive strategy for reducing total energy content of the diet and promoting 
healthy body weight. 
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TFAs 
Specific Fatty Acids and Food Sources 
Partial hydrogenation results in the formation of a large number of posi-
tional and geometric isomers of the naturally occurring cis-fatty acids. A ma-
jor TFA in industrially hydrogenated oils is elaidic acid (18:1, t9), although 
many other trans isomers are formed. TFA are present in ruminant meat and 
milk fats as a result of biohydrogenation of unsaturated fatty acids (18:2 and 
18:3) in the rumen. The major TFA in ruminant meat and dairy products are 
c9,t11-CLA, with vaccenic acid (18:1, t11), predominating at 50% to 80% of 
total ruminant TFA (rTFA) produced. Recent efforts to increase c9,t11-CLA 
content in ruminants has increased the presence of rTFA in both meat and 
dairy products.117 As previously stated, CLA is classified as an n-6 fatty acid 
and not a TFA and, therefore, will not be discussed here. Sources of commer-
cially partially hydrogenated TFA include hydrogenated vegetable and ma-
rine oils; these oils have been commonly used in commercial baked goods. 
Although the TFA content in foods has decreased recently (through food re-
formulation), it is important to monitor the type of fat used to replace TFA, 
as it might be SFA. 
An FDA labeling requirement that went into effect in 2006 required food 
labels to list TFA on their Nutrition Facts panel (on a separate line under the 
saturated fat listing) when present at 0.5 g or more per serving. Dietary sup-
plements were also required to list TFA in the Supplement Facts panel. If the 
TFA content is <0.5 g per serving, then TFA does not need to be listed. Con-
sumption of foods that contain TFA but at <0.5 g per serving contribute to 
overall TFA intake, so foods commonly containing TFA should continue to 
be limited (e.g., commercial pastries, cookies, fast food). In addition, the FDA 
has recently issued a Federal Register notice preliminarily determining that 
trans fats (partially hydrogenated oils) are no longer “generally recognized 
as safe,” or GRAS. RDNs should monitor the determination of the FDA re-
garding GRAS status of trans fats and what this means to the availability of 
trans fats to the consumer. 
TFA from Supplements 
No TFA supplements currently exist, as their negative health impacts are 
widely known. However, this excludes CLA, considered a TFA, as the cis-9, 
trans-11 CLA isomers contain a trans bond at cis-11. Although nutritional 
supplements in liquid or powder form can contain trans fats, and must de-
clare it on the label if ≥0.5 g per serving, the majority of the products do 
not contain appreciable quantities. 
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Current Dietary Intake of TFAs 
Recent intake data estimates that TFA intake is 3 to 4 g/day in North Amer-
ica; intake is similar in northern European countries and less in eastern Asian 
countries (<1 g/day). This is a reduction from previous consumption, which 
was estimated to be 10 g/day worldwide.118 Data from the European TRANS-
FAIR study indicate that in the United States, 1.2 g/day of TFA originates from 
ruminants. This is comparable with other countries, as consumption of rTFA 
in Europe ranges from 0.8 to 1.7 g/day.119 More recent evidence (2007) re-
ports the consumption of rTFA is 20% of total TFA intake, with most (85%) 
of this coming from milk fat. Recent analysis of NHANES 2003-2006 dietary 
data indicate industrially produced TFA intake at 1.3 g per person per day.120 
This is a reduction from 4.6 g per day, as stated in the FDA ruling (2003), 
which established labeling requirements for TFA intake; this reflects a re-
duction of TFAs in processed foods. TFA intake is declining; a recent com-
parison using NHANES data indicated a 58% decrease in serum TFA levels 
from 2000-2009.121 
TFA Recommendations 
The 2005 Daily Reference Intake has not set an AI or RDA for TFAs. No up-
per limit is set, as any TFA intake increases CHD risk; in light of this, intake of 
TFA should be kept as low as possible.9 The DGA also recommend TFA con-
sumption to be as low as possible, especially by limiting foods that contain 
synthetic sources of TFA, such as partially hydrogenated oils, and by limiting 
other solid fats.5 The AHA’s Diet and Lifestyle Recommendations advocate 
that TFA be <1% of calories.3 In 2008, the FAO/ World Health Organization 
recommended a TFA upper limit (both ruminant and industrially produced) 
to be <1% of energy; a 2010 report acknowledged that the <1% recom-
mendation might need to be revisited due to unknown distribution of in-
take and potential negative impact on subgroups with higher consumption.6 
TFAs and Health 
The impact of TFA intake is generally undisputed. There is convincing ev-
idence that consumption of commercial partially hydrogenated vegetable 
oils increases CHD risk factors, as well as in metabolic syndrome and diabe-
tes risk. For example, trans-C18:1 increased serum levels of lipoprotein(a), 
an atherogenic protein associated with apolipoprotein B-containing lipo-
proteins; as this is the most commonly consumed TFA, this finding may 
be important with regard to risk of disease in healthy individuals.122 Lim-
ited research has examined the different impacts of industrially produced 
TFA and rTFA on CHD risk. The amount of TFA is also relevant when con-
sidering the impact on disease risk markers. At 3.7% of energy, both rumi-
nant and industrial TFA have been shown to have adverse effects on blood 
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lipids, specifically increases in LDL cholesterol and decreases in HDL choles-
terol. However, when examined at lower doses (1.5% of energy from rTFA 
or 0.8% total TFA), no significant differences in blood lipids or lipoproteins 
were seen.123 A relationship between trans fats and cancer has not been de-
termined.106 In summary, foods containing industrially derived TFA should be 
minimized. Due to recent changes in commercial food composition, there 
is less TFA in foods. Nonetheless, consumers should be cognizant of poten-
tial TFA in processed foods and limit fast food in the diet in order to reduce 
TFA intake, ideally to <1% of energy. Replacing TFA with other fatty acids or 
carbohydrate is an improvement, but replacing TFA with PUFA is most ben-
eficial for health. 
Emerging Population Research 
Nutrition research is the basis for ongoing revisions in dietary recommen-
dations. Large and long-term investigations into the impact of specific fatty 
acid groups on public health are emerging. In a recent study, associations 
between type of dietary fat intake—PUFA, MUFA and SFA—and CHD risk 
were assessed using data from 11 American and European cohort stud-
ies to address the question of the best macronutrient substitution for SFA 
in the diet. From follow-up data over 4 to 10 years including 344,696 per-
sons, researchers identified that replacing SFA with PUFA was preferable 
to MUFA and carbohydrate for reducing CHD risk; a 5% decrease in SFA 
that was replaced with PUFA showed an inverse and significant relation-
ship with CHD.98 The EPIC (European Prospective Investigation of Cancer)-
Norfolk study involving 25,639 individuals reported blood levels of SFA 
were positively associated with CHD risk, while an inverse association was 
seen with PUFA levels.11 In addition, a 2012 study from a prospective co-
hort among 91,981 women in the Nurses’ Health Study reported that con-
sumption of PUFAs as a proportion of fat was inversely associated with 
risk of sudden cardiac death, independent of traditional CHD risk factors.12 
Together, these data support dietary guidelines to replace intake of SFAs 
with n-3 and n-6 PUFAs. 
American and international health and government organizations agree 
with recommendations to consume 7% to 10% of total calories as SFA and 
restrict consumption of trans fat. The optimal intake of MUFA is undeter-
mined, and the optimal amount of n-3 and n-6 fats to consume within the 
PUFA category also remains unanswered. Many but not all fats and oils that 
contain n-6 fatty acids also contain some plant-based n-3s. Physiological 
differences between plant-based and marine-source n-3s exist and experts 
agree that increasing intake of n-3 is warranted. An upper intake level of 2% 
energy as n-3 and 10% energy as n-6 is recommended, but it might also be 
time to review these recommendations.124,125 
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Role of the RDN and DTR Team 
Fat is a valuable macronutrient in human health. RDNs and DTRs, under the 
supervision of the RDN, can help clients set and maintain realistic goals for 
intake of total fat and fatty acids, thereby influencing lifelong health and 
weight. This requires providing guidance on the quantity and quality of di-
etary fat in addition to meal planning and food preparation. The guiding 
philosophy is to encourage food-based consumption first and supplements 
second. Monitoring total fat is important because it is abundant in the diet 
and contributes to excessive energy intake; however, it aids absorption of 
fat-soluble nutrients and provides desirable cooking and sensory qualities. 
Monitoring type of fatty acid is important because they each have differ-
ent biological effects in the body and some are essential in human nutri-
tion. Recommendations for specific foods (e.g., avocados) or fatty acids (e.g., 
more n-3) might be more practical than general statements. The concept 
of caloric density is relevant because fat contains 9 calories per gram, more 
than double the calories per gram of protein and carbohydrates. Replacing 
fat with less calorically dense foods or without caloric replacement, within 
the context of adequate nutrition, are effective strategies for limiting excess 
energy intake; helping patients make appropriate substitutions is equally 
important. Understanding, for example, that individuals who consume fried 
fish tend to consume higher amounts of SFA and TFA is useful when offer-
ing guidance.47 Providing clients with helpful tools and resources, for exam-
ple, how to choose snack foods with less SFA or fish that is recommended by 
environmental organizations, will support ongoing healthful choices. Teach-
ing consumers how to understand and apply Nutrition Facts labels and in-
gredient lists has lasting results. 
In addition to current knowledge, information on how fatty acids influ-
ence health through gene expression is forthcoming. For example, both the 
type and amount of PUFA influence peroxisome proliferator-activated re-
ceptor activity and its regulation of lipid metabolism, including lipogene-
sis, oxidation, and transport.126 In addition, research on how an individual’s 
genetic variation influences fatty acid utilization is underway; this work will 
provide rationale and direction for future individualized dietary prescrip-
tions. For example, individuals carrying >2 signal transducer and activator 
of transcription 3 (STAT3) risk alleles have increased risk of obesity with a 
SFA intake of >15.5% of energy, compared with those with ≤1 risk allele.127 
Knowledge gained in this area of research will enable RDNs to customize 
diets for optimal health outcomes. 
Nutrition science has moved beyond fat as a macronutrient; a command-
ing knowledge of food sources and health impact of individual fatty acids 
is a vital piece of RDN training and continuing education. It is essential that 
RDNs understand the current literature on dietary fat and fatty acids and 
build knowledge as science expands. Translating fat and fatty acid literature 
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into dietary recommendations is a complex process yet highly suited for 
the skills and training of RDNs. New technologies are changing the types of 
fatty acids in the food supply: new sources of fatty acids are being discov-
ered, structural changes within the fatty acids and how they are positioned 
within the triglyceride molecule are being made, and genetically engineered 
fatty acids are being incorporated into new foods. As modified fatty acids 
and their sources become available, RDNs will be called on to provide lead-
ership and guidance in areas where the science is still emerging. 
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